1. Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.
- Author
-
Qian, Jun, Lin, Jiang, Qian, Wei, Ma, Ji-chun, Qian, Si-xuan, Li, Yun, Yang, Jing, Li, Jian-yong, Wang, Cui-zhu, Chai, Hai-yan, Chen, Xing-xing, and Deng, Zhao-qun
- Subjects
- *
ACUTE myeloid leukemia treatment , *MICRORNA , *CARCINOGENESIS , *APOPTOSIS , *CELL migration , *POLYMERASE chain reaction - Abstract
Abstract: MicroRNA miR-378 plays important roles in tumorigenesis by enhancing cell survival, reducing apoptosis, promoting tumor growth, angiogenesis and promoting cell migration and invasion. Abnormal expression of miR-378 has been observed in various types of cancers. The aim of this study was to investigate the expression status of miR-378 and its clinical significance in patients with acute myeloid leukemia (AML) using real-time quantitative PCR. miR-378 overexpression was identified in 26 of 84 (31%) AML patients. The patients with miR-378 overexpression had lower hemoglobin level than those without miR-378 overexpression (66 versus 78g/L, respectively, P =0.010). The frequency of miR-378 overexpression in FAB-M2 subtype was higher than other subtypes (44% versus 20%, P =0.032). Moreover, the frequency of miR-378 overexpression was higher in patients with t(8;21) than in others (64% versus 24%, P =0.012). The status of miR-378 expression was not correlated with the mutations of eight genes (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, C/EBPA and U2AF1). The difference in relapse-free survival was observed between patients with and without miR-378 overexpression (P =0.049). These findings suggest that miR-378 up-regulation is a common event and might have an adverse impact on prognosis in AML. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF